X
[{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"WuXi AppTec Inc.","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Simcha debuts with $25M to advance custom-built IL-18 for cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Simcha Therapeutics Shares Data at AACR Annual Meeting Highlighting Potent Preclinical Efficacy of Decoy-Resistant IL-18 Cytokine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Simcha Therapeutics Raises $40 Million Series B Financing and Initiates Phase 1\/2 Study to Evaluate Novel Interleukin-18 Variant in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcha Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ST-067 in Combination with KEYTRUDA\u00ae (Pembrolizumab) in Patients with Various Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Simcha Therapeutics Announces License & Option Agreement to Develop Novel Decoy-resistant IL-18 for Use in Cell Therapy Applications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Simcha Therapeutics
Filters
Companies By Therapeutic Area
Details:
Under the terms of the agreement, Janssen will develop, manufacture, and commercialize CAR T-based cell therapy candidates with Simcha’s novel proprietary decoy-resistant IL-18 (DR-18) for a set number of programs.
Lead Product(s):
CAR T-based Cell Therapy
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
JANSSEN BIOTECH
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
January 08, 2024
Details:
The collaboration aims to evaluate clinical safety and benefits of ST-067, Simcha’s decoy resistant IL-18 agent, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with solid tumors.
Lead Product(s):
ST-067,Pembrolizumab
Therapeutic Area: Oncology
Product Name: ST-067
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Merck & Co
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
April 05, 2023
Details:
In addition, the Company has dosed the first patient in the Phase 1 portion of a first-in human multi-center Phase 1/2 clinical trial of its first drug candidate ST-067, a first-in-class “decoy-resistant” Interleukin-18 variant.
Lead Product(s):
ST-067
Therapeutic Area: Oncology
Product Name: ST-067
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
BVF Partners
Deal Size: $40.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
January 27, 2022
Details:
Simcha’s lead program involves a customized variant of interleukin-18 (IL-18), a cytokine with potent antitumor effects, developed in the lab of Scientific Founder Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School of Medicine.
Lead Product(s):
ST-067
Therapeutic Area: Oncology
Product Name: ST-067
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
WuXi AppTec Inc.
Deal Size: $25.0 million
Upfront Cash: Undisclosed
Deal Type: Series A Financing
June 24, 2020
Details:
Oral presentation and poster detail DR-18’s ability to re-animate exhausted NK cells, bias differentiation of T cells toward highly active effectors and expand the population of critical immune cells inside the tumor microenvironment.
Lead Product(s):
DR-18
Therapeutic Area: Oncology
Product Name: DR-18
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 24, 2020